Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin
Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin
复制标题
DOI：
10.3892/or.2011.1151
复制
发表时间：
2011-04-01
期刊：
影响因子：
4.2
通讯作者：
Udagawa, Yasuhiro
中科院分区：
文献类型：
--
作者：
Komiyama, Shinichi;Kurahashi, Takashi;Udagawa, Yasuhiro
研究表明，TGF β 1及其受体[TGF β I型受体（T β RI）和TGF β II型受体（T β RII）]的表达可能在上皮性卵巢癌的增殖和进展中起关键作用。我们研究了TGF β 1及其受体的生物学意义，以及它们与紫杉醇（PTX）和卡铂（CBDCA）的肿瘤反应的关系。我们研究了24例卵巢癌、原发性腹膜癌或输卵管癌患者，他们接受了手术和PTX和CBDCA化疗。检查原发肿瘤组织，并通过RNA酶保护试验评估TGF β 1、T β RI和T β RII mRNA的表达。结果发现，TGF β 1 mRNA的表达显着低于患者的肿瘤谁有最佳的手术比次优手术的患者的肿瘤。对PTX和CBDCA敏感性高的肿瘤中TGF β 1 mRNA表达也显著低于敏感性低的肿瘤。T β RI mRNA表达与临床病理因素无关。透明细胞腺癌和粘液腺癌中T β R Ⅱ mRNA表达明显增高，浆液性腺癌和类浆液性腺癌中T β R Ⅱ mRNA表达较低。此外，与晚期肿瘤相比，早期肿瘤中的表达往往更高。在TGF β 1、T β RI和T β RII中，TGF β 1 mRNA的表达与无进展生存期的相关性最强。当基于TGF β 1 mRNA表达比较晚期癌症患者的预后时，肿瘤显示低表达的患者倾向于比肿瘤显示高表达的患者具有更好的预后。这表明TGF β 1 mRNA表达是肿瘤对PTX和CBDCA标准治疗敏感性的指标，它可以识别生物学侵袭性和高度恶性肿瘤，并可以预测卵巢癌患者的预后。
It has been suggested that expression of TGF beta 1 and its receptors [TGF beta receptor type I (T beta RI) and TGF beta receptor type II (T beta RII)] may play a key role in the proliferation and progression of epithelial ovarian cancer. We investigated the biological significance of TGF beta 1 and its receptors, as well as their association with the tumor response to paclitaxel (PTX) and carboplatin (CBDCA). We studied 24 patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who had undergone surgery and chemotherapy with PTX and CBDCA. Tissues from the primary tumor were examined and the expression of TGF beta 1, T beta RI, and T beta RII mRNA was assessed by the RNase protection assay. It was found that TGF beta 1 mRNA expression was significantly lower in the tumors of patients who had optimal surgery than in the tumors of patients with suboptimal surgery. TGF beta 1 mRNA expression was also significantly lower in tumors with high sensitivity to PTX and CBDCA than in those with low sensitivity. T beta RI mRNA expression was not associated with any clinicopathological factors. Expression of T beta RII mRNA was significantly higher in clear cell adenocarcinoma and mucinous adenocarcinoma, while it was lower in serous adenocarcinoma and endometrioid adenocarcinoma. Moreover, it tended to be higher in early-stage tumors compared with advanced tumors. Among TGF beta 1, T beta RI, and T beta RII, expression of TGF beta 1 mRNA was most strongly associated with progression-free survival. When the prognosis of the patients with advanced cancer was compared on the basis of TGF beta 1 mRNA expression, those whose tumors showed low expression tended to have a better prognosis than those whose tumors showed high expression. It is suggested that TGF beta 1 mRNA expression is an indicator of tumor sensitivity to standard therapy with PTX and CBDCA, that it can identify biologically aggressive and highly malignant tumors and that it can predict the prognosis of patients with ovarian cancer.